Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Werewolf Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 65 | 1 | 62 | −2 |
| Shares | 22.3M | 10.2K | 21.1M | −1.20M (−5.4%) |
| Value | $24.3M | $11.1K | $41.6M | +$17.3M (+71.0%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 154,534 | $304.4K | 0.00% |
| Cubist Systematic Strategies, LLC | 46,711 | $92.0K | 0.00% |
| Virtu Financial LLC | 12,230 | $24.0K | 0.00% |
| Cetera Investment Advisers | 10,200 | $20.1K | 0.00% |
| Group One Trading, L.P. | 2,671 | $5.26K | 0.00% |
| Advisory Services Network, LLC | 157 | $309 | 0.00% |
| SRS Capital Advisors, Inc. | 68 | $133 | 0.00% |
| Optiver Holding B.V. | 22 | $43 | 0.00% |
Sold out (10)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Marshall Wace, LLP | 103,785 | $113.1K |
| Y-Intercept (Hong Kong) Ltd | 84,421 | $92.0K |
| Jain Global LLC | 26,983 | $29.4K |
| Quadrature Capital Ltd | 25,791 | $28.0K |
| Two Sigma Securities, LLC | 22,409 | $24.4K |
| Jump Financial, LLC | 11,345 | $12.4K |
| Wells Fargo & Company | 459 | $500 |
| Point72 (DIFC) Ltd | 403 | $439 |
| Essential Partners LLC | 52 | $57 |
| True Wealth Design, LLC | 13 | $15 |
Not filed for Q3 2025 yet (1)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Avantax Advisory Services, Inc. | 10,200 | $11.1K |